ESPERION THERAPEUTICS ($ESPR) posted quarterly earnings results for Q4 2025 on Tuesday, March 10th. The company reported earnings of $0.22 per share, missing estimates of $0.26 by $0.04. The company also reported revenue of $168,450,000, missing estimates of $182,203,844 by $-13,753,844.
You can see Quiver Quantitative's $ESPR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ESPERION THERAPEUTICS Insider Trading Activity
ESPERION THERAPEUTICS insiders have traded $ESPR stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $ESPR stock by insiders over the last 6 months:
- SHELDON L. KOENIG (President and CEO) has made 0 purchases and 2 sales selling 76,671 shares for an estimated $256,454.
- BENJAMIN LOOKER (General Counsel) has made 0 purchases and 4 sales selling 15,721 shares for an estimated $49,613.
- BENJAMIN HALLADAY (Chief Financial Officer) has made 0 purchases and 2 sales selling 14,383 shares for an estimated $46,689.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ESPERION THERAPEUTICS Hedge Fund Activity
We have seen 124 institutional investors add shares of ESPERION THERAPEUTICS stock to their portfolio, and 78 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- D. E. SHAW & CO., INC. added 6,694,850 shares (+3208.9%) to their portfolio in Q4 2025, for an estimated $24,770,945
- ORBIMED ADVISORS LLC added 5,965,498 shares (+inf%) to their portfolio in Q4 2025, for an estimated $22,072,342
- EVERSEPT PARTNERS, LP added 3,851,133 shares (+inf%) to their portfolio in Q4 2025, for an estimated $14,249,192
- INDABA CAPITAL MANAGEMENT, L.P. removed 3,000,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $7,950,000
- MILLENNIUM MANAGEMENT LLC added 2,957,418 shares (+303.4%) to their portfolio in Q4 2025, for an estimated $10,942,446
- MARSHALL WACE, LLP added 2,950,172 shares (+117.0%) to their portfolio in Q4 2025, for an estimated $10,915,636
- VANGUARD GROUP INC added 2,853,005 shares (+23.6%) to their portfolio in Q4 2025, for an estimated $10,556,118
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ESPERION THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $ESPR in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 11/25/2025
To track analyst ratings and price targets for ESPERION THERAPEUTICS, check out Quiver Quantitative's $ESPR forecast page.
ESPERION THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $ESPR recently. We have seen 3 analysts offer price targets for $ESPR in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- Serge Belanger from Needham set a target price of $5.0 on 03/03/2026
- David Amsellem from Piper Sandler set a target price of $9.0 on 11/25/2025
- Joseph Pantginis from HC Wainwright & Co. set a target price of $16.0 on 09/19/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
